MoonLake Immunotherapeutics (MLTX): who owns it and who trades it
As of Nov 16, 2026, MLTX insiders reported 26 open-market sales worth $81.1M and no purchases in the last 12 months, with 14% of the sale value made under pre-set 10b5-1 plans. The largest seller was Mark N Lampert (Director), with $63M. 5 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling MoonLake Immunotherapeutics
From the latest filingsOverall: about as much buying as selling. Insiders mostly sold. Funds and famous investors mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns MLTX
173 funds and institutions reported MLTX shares worth $1.5B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is Bvf Inc with 21.7%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Bvf Inc | 16.00M | 21.74% | $312M | No change |
| Deep Track Capital, LP | 7.00M | 9.51% | $136M | +9% |
| T. Rowe Price Investment Management, Inc. | 4.28M | 5.81% | $83.3M | – |
| D. E. Shaw & Co., Inc. | 3.37M | 4.57% | $65.5M | +41% |
| Cormorant Asset Management, LP | 3.21M | 4.35% | $62.4M | -28% |
| Jupiter Topco LLC | 3.09M | 4.19% | $60.1M | – |
| Logos Global Management LP | 2.67M | 3.63% | $52.1M | +78% |
| Weiss Asset Management LP | 2.58M | 3.51% | $50.3M | +51% |
| Citadel Advisors LLC | 1.97M | 2.68% | $38.4M | +49% |
| Two Sigma Investments, LP | 1.72M | 2.33% | $33.4M | +53% |
| Mpm Bioimpact LLC | 1.61M | 2.18% | $31.3M | -11% |
| Vivo Capital, LLC | 1.40M | 1.90% | $27.3M | +40% |
| JPMorgan Chase & Co | 1.39M | 1.88% | $27.6M | – |
| Point72 Asset Management, L.P. | 1.16M | 1.57% | $22.6M | -15% |
| BlackRock, Inc. | 1.09M | 1.49% | $21.3M | +7% |
| T. Rowe Price Associates | 1.04M | 1.41% | $20.3M | -20% |
| Balyasny Asset Management L.P. | 912,715 | 1.24% | $17.8M | -14% |
| Great Point Partners LLC | 855,813 | 1.16% | $16.7M | +71% |
| Jane Street Group, LLC | 853,386 | 1.16% | $16.6M | +88% |
| Candriam S.C.A. | 769,766 | 1.05% | $15M | -6% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, MLTX insiders reported $0 of open-market purchases and $81.1M of sales. 14% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Jul 27, 2026 | Kristian Reich | Chief Scientific Officer | Sale plan | 1,100 | $20.00 | $22K | Form 4 |
| Jul 22, 2026 | Kristian Reich | Chief Scientific Officer | Sale plan | 2,448 | $20.00 | $49K | Form 4 |
| Jul 21, 2026 | Kristian Reich | Chief Scientific Officer | Sale plan | 50,000 | $20.02 | $1M | Form 4 |
| Jul 20, 2026 | Kristian Reich | Chief Scientific Officer | Sale plan | 43,700 | $20.09 | $878K | Form 4 |
| Jul 15, 2026 | Kristian Reich | Chief Scientific Officer | Sale plan | 16,105 | $20.01 | $322K | Form 4 |
| Jul 10, 2026 | da Silva Jorge Santos | CEO | Sale plan | 68,289 | $20.02 | $1.4M | Form 4 |
| Jul 9, 2026 | da Silva Jorge Santos | CEO | Sale plan | 33,936 | $20.01 | $679K | Form 4 |
| Jul 1, 2026 | da Silva Jorge Santos | CEO | Sale plan | 47,775 | $20.03 | $957K | Form 4 |
| Jun 22, 2026 | Matthias Bodenstedt | CFO | Sale plan | 39,120 | $22.04 | $862K | Form 4 |
| Jun 18, 2026 | Matthias Bodenstedt | CFO | Sale plan | 2,794 | $19.60 | $54.8K | Form 4 |
| Jun 17, 2026 | Matthias Bodenstedt | CFO | Sale plan | 15,082 | $19.68 | $297K | Form 4 |
| Jun 17, 2026 | Kristian Reich | Chief Scientific Officer | Sale plan | 50,000 | $19.43 | $972K | Form 4 |
| Jun 16, 2026 | Kristian Reich | Chief Scientific Officer | Sale plan | 50,000 | $18.70 | $935K | Form 4 |
| Jun 15, 2026 | Kristian Reich | Chief Scientific Officer | Sale plan | 50,000 | $18.89 | $944K | Form 4 |
| May 11, 2026 | Matthias Bodenstedt | CFO | Sale plan | 13,653 | $20.02 | $273K | Form 4 |
| Apr 14, 2026 | Matthias Bodenstedt | CFO | Sale plan | 2,426 | $19.56 | $47.5K | Form 4 |
| Apr 13, 2026 | da Silva Jorge Santos | CEO | Sale | 51,873 | $18.23 | $946K | Form 4 |
| Apr 10, 2026 | da Silva Jorge Santos | CEO | Sale | 98,127 | $18.41 | $1.8M | Form 4 |
| Apr 10, 2026 | Matthias Bodenstedt | CFO | Sale plan | 1,925 | $19.51 | $37.6K | Form 4 |
| Apr 9, 2026 | Matthias Bodenstedt | CFO | Sale plan | 85,870 | $18.94 | $1.6M | Form 4 |
| Mar 31, 2026 | Mark N Lampert +9 | Director | Sale | 1.93M | $16.79 | $32.4M | Form 4 |
| Mar 31, 2026 | Mark N Lampert +9 | Director | Sale | 1.57M | $16.79 | $26.3M | Form 4 |
| Mar 31, 2026 | Mark N Lampert +9 | Director | Sale | 248,530 | $16.79 | $4.2M | Form 4 |
| Dec 9, 2025 | da Silva Jorge Santos | CEO | Sale | 70,000 | $14.49 | $1M | Form 4 |
| Dec 9, 2025 | Kristian Reich | Chief Scientific Officer | Sale | 72,908 | $14.43 | $1.1M | Form 4 |
| Dec 8, 2025 | da Silva Jorge Santos | CEO | Sale | 130,000 | $15.08 | $2M | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Mark N Lampert | Director, 10% owner | – | $63M | Mar 31, 2026 |
| da Silva Jorge Santos | Chief Executive Officer, Director | – | $8.7M | Jul 10, 2026 |
| Kristian Reich | Chief Scientific Officer | – | $6.2M | Jul 27, 2026 |
| Matthias Bodenstedt | Chief Financial Officer | – | $3.2M | Jun 22, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
MLTX short interest
Moderate short interest. 6.4% of MLTX shares are sold short: about 1 share in 16. Over the last 12 reports the number of shares short barely changed.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 5.47M MLTX shares were sold short, 6.4% of the shares outstanding, down 30.1% from the report before. At the average daily volume of 1.92M shares, buying them all back would take about 2.9 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 5.47M | 6.43% | -30% | 1.92M | 2.9 |
| Oct 15, 2026 | 7.83M | 9.20% | -3% | 1.92M | 4.1 |
| Sep 30, 2026 | 8.05M | 9.46% | -10% | 1.90M | 4.2 |
| Sep 15, 2026 | 8.95M | 10.51% | +25% | 1.47M | 6.1 |
| Aug 31, 2026 | 7.14M | 8.39% | +5% | 1.07M | 6.7 |
| Aug 14, 2026 | 6.82M | 8.01% | +19% | 1.62M | 4.2 |
| Jul 31, 2026 | 5.72M | 7.77% | -10% | 864,693 | 6.6 |
| Jul 15, 2026 | 6.33M | 8.60% | -3% | 1.27M | 5.0 |
| Jun 30, 2026 | 6.56M | 8.91% | +23% | 1.86M | 3.5 |
| Jun 15, 2026 | 5.32M | 7.23% | -4% | 736,814 | 7.2 |
| May 29, 2026 | 5.57M | 7.56% | +2% | 803,977 | 6.9 |
| May 15, 2026 | 5.47M | 7.43% | -13% | 1.10M | 5.0 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
MoonLake Immunotherapeutics company events
MoonLake Immunotherapeutics filed 11 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Nov 4, 2026.
- Nov 4, 2026ResultsReleased financial results. Filing
- Sep 30, 2026AnnouncementMoonLake Immunotherapeutics submitted a Biologics License Application to the U.S. Food and Drug Administration, seeking approval of its tri-specific nanobody sonelokimab for the treatment of moderate-to-severe hidradenitis suppurativa in adults and pediatric patients 12 years of age and older. Filing
- Aug 10, 2026ResultsReleased financial results. Filing
- Jul 15, 2026AnnouncementThe underwriters of the previously announced public offering of Class A ordinary shares, par value $0.0001 per share, of MoonLake Immunotherapeutics and, in lieu of Ordinary Shares to certain investors that so choose, pre-funded warrants to purchase Ordinary Shares, exercised in full their option… Filing
- Jun 25, 2026AgreementMoonLake Immunotherapeutics entered into an underwriting agreement with Leerink Partners LLC, as the representative of the underwriters named therein, to issue and sell, in a public offering, 9,000,000 Class A ordinary shares, par value $0.0001 per share, at a public offering price of $20.00 per… Filing
- Jun 22, 2026AnnouncementResults from the Phase 3 VELA clinical trials at Week 52 Week 52 data for SLK showed consistent and further improvement in all clinical scores, compared to Week 16 data. Filing
- Jun 9, 2026LeadershipDeparture of Director or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Filing
- Jun 1, 2026AgreementMoonLake Immunotherapeutics entered into a Master Commercial Supply Agreement with Vetter Pharma International GmbH. Filing
- May 11, 2026ResultsReleased financial results. Filing
- Feb 23, 2026LeadershipSimon Sturge notified the Board of Directors of the Company of his intent to resign as a member of the Board, effective as of February 28, 2026. Filing
- Jan 8, 2026AnnouncementMoonLake Immunotherapeutics issued a press release providing an update following the positive feedback received from the U.S. Food and Drug Administration regarding the clinical evidence strategy for Sonelokimab in Hidradenitis Suppurativa, based on the Type B meeting requested by the Company. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
MoonLake Immunotherapeutics financials
Famous investors that hold MLTX
5 of the 50 well-known investors we track reported holding MLTX in their latest 13F filing. The largest position is Jim Simons's, worth $20.1M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Jim Simons · Renaissance Technologies | Q3 2026 | 1.72M | $20.1M | 0.0% | +167% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 1.71M | $20M | 0.0% | -14% |
| Israel Englander · Millennium Management | Q3 2026 | 1.53M | $18M | 0.0% | +141% |
| Stanley Druckenmiller · Duquesne Family Office | Q3 2026 | 494,000 | $5.8M | 0.1% | New |
| Paul Tudor Jones · Tudor Investment Corp | Q3 2026 | 45,612 | $534K | 0.0% | -22% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
Questions about MoonLake Immunotherapeutics (MLTX) stock
Who owns the most MLTX stock?
The largest reported owner of MoonLake Immunotherapeutics (MLTX) is Bvf Inc, with 21.7% of the company. In total, 173 funds and institutions reported holding MLTX at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are MLTX insiders buying or selling?
In the last 12 months, MLTX insiders reported no open-market purchases and 26 sales worth $81.1M. The latest trade was on Jul 27, 2026. See every trade.
What is the short interest in MLTX?
As of Oct 30, 2026, 5.47M MLTX shares were sold short, 6.4% of the shares outstanding, down 30.1% from the report before. At the average daily volume of 1.92M shares, buying them all back would take about 2.9 trading days (days to cover). See the history.
Which famous investors hold MLTX?
5 of the 50 well-known investors we track reported MLTX in their latest 13F filing, including Jim Simons, Ken Griffin, Israel Englander. The largest position is worth $20.1M. See all holders.
Executive pay
MoonLake Immunotherapeutics's chief executive was paid a total of $4.9M for the year ended Dec 31, 2025, up 252% from $1.4M the year before. In the last 12 months, MoonLake Immunotherapeutics's executives and directors bought no stock on the open market and sold $81.1M.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.